Brief Summary

The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and healthcare-associated pneumonia (HCAP) in real life of China .

Trial Health

At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date

Enrollment

3,000

participants targeted

Target at P75+ for all trials

Timeline

Completed

Started Jul 2015

Geographic Reach

1 country

1 active site

Status

unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

1.4 years study duration

First Submitted

Initial submission to the registry

March 16, 2015

Completed

4 months until next milestone

Study Start

First participant enrolled

July 1, 2015

Completed

2 days until next milestone

First Posted

Study publicly available on registry

July 3, 2015

Completed

1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed

Last Updated

October 16, 2015

Status Verified

October 1, 2015

Enrollment Period

1.4 years

First QC Date

March 16, 2015

Last Update Submit

October 14, 2015

Conditions

Community Acquired Pneumonia

Keywords

Community Acquired Pneumoniahealth care associated pneumonia

Outcome Measures

Primary Outcomes (2)

treatment failure at 72h after initiation of antibiotics
treatment failure was defined as a change of antibiotics due to worsening signs or symptoms associated with pneumonia
Time from the first dose use of antibiotics to 72 hours
in-hospital treatment failure due to multiple causes
1)death in hospital;2)change of antibiotics due to worsening signs or symptoms of infection, 3) recurrence, defined as signs or symptoms of infection after completion of therapy requiring re-initiation of antibiotics
Time from date of admission to discharge up to 1 week

Secondary Outcomes (3)

Duration of intravenous antimicrobial therapy
2 weeks
Hospital length of stay
2 weeks
in-hospital mortality
2 weeks

Interventions

otherOTHER

retrospective cohort study

Eligibility Criteria

Age14 Years+

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

3000 patients with community acquired pneumonia who meet the below inclusion/ exclusion criteria will be recruited in China.

You may qualify if:

Patients \> or = 14 years of age
Patient meets the criteria of community acquired pneumonia
Patient meets the criteria of healthcare-associated pneumonia

You may not qualify if:

Patients \<14 years of age
Patient meets the criteria of hospital acquired pneumonia
Known active tuberculosis or current treatment for tuberculosis
Non-infectious pulmonary diseases
HIV positive

Contact the study team to confirm eligibility.

Study Sites (1)

China-Japan Friendship Hospital

Beijing, 100029, China

RECRUITING

Related Publications (7)

Yang SQ, Qu JX, Wang C, Yu XM, Liu YM, Cao B. Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post-pandemic period. Clin Respir J. 2014 Apr;8(2):185-91. doi: 10.1111/crj.12056. Epub 2013 Nov 26.
PMID: 24106842RESULT
Cao B, Huang GH, Pu ZH, Qu JX, Yu XM, Zhu Z, Dong JP, Gao Y, Zhang YX, Li XH, Liu JH, Wang H, Xu Q, Li H, Xu W, Wang C. Emergence of community-acquired adenovirus type 55 as a cause of community-onset pneumonia. Chest. 2014 Jan;145(1):79-86. doi: 10.1378/chest.13-1186.
PMID: 24551881RESULT
Qu J, Gu L, Wu J, Dong J, Pu Z, Gao Y, Hu M, Zhang Y, Gao F, Cao B, Wang C; Beijing Network for Adult Community-Acquired Pneumonia (BNACAP). Accuracy of IgM antibody testing, FQ-PCR and culture in laboratory diagnosis of acute infection by Mycoplasma pneumoniae in adults and adolescents with community-acquired pneumonia. BMC Infect Dis. 2013 Apr 11;13:172. doi: 10.1186/1471-2334-13-172.
PMID: 23578215RESULT
Han X, Wang H, Chen L, Wang Y, Li H, Zhou F, Xing X, Zhang C, Suo L, Wang J, Yu G, Wang G, Yao X, Yu H, Wang L, Liu M, Xue C, Liu B, Zhu X, Li Y, Xiao Y, Cui X, Li L, Liu X, Cao B. Impact of inhaled corticosteroid use on elderly chronic pulmonary disease patients with community acquired pneumonia. Chin Med J (Engl). 2024 Jan 20;137(2):241-243. doi: 10.1097/CM9.0000000000002936. Epub 2023 Dec 20. No abstract available.
PMID: 38111015DERIVED
Han X, Liu X, Chen L, Wang Y, Li H, Zhou F, Xing X, Zhang C, Suo L, Wang J, Yu G, Wang G, Yao X, Yu H, Wang L, Liu M, Xue C, Liu B, Zhu X, Li Y, Xiao Y, Cui X, Li L, Cao B; CAP-China network. Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients. BMC Infect Dis. 2020 Sep 12;20(1):668. doi: 10.1186/s12879-020-05362-3.
PMID: 32919458DERIVED
Han X, Zhou F, Li H, Xing X, Chen L, Wang Y, Zhang C, Liu X, Suo L, Wang J, Yu G, Wang G, Yao X, Yu H, Wang L, Liu M, Xue C, Liu B, Zhu X, Li Y, Xiao Y, Cui X, Li L, Purdy JE, Cao B; CAP-China network. Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia. BMC Infect Dis. 2018 Apr 24;18(1):192. doi: 10.1186/s12879-018-3098-5.
PMID: 29699493DERIVED
Chen L, Zhou F, Li H, Xing X, Han X, Wang Y, Zhang C, Suo L, Wang J, Yu G, Wang G, Yao X, Yu H, Wang L, Liu M, Xue C, Liu B, Zhu X, Li Y, Xiao Y, Cui X, Li L, Uyeki TM, Wang C, Cao B; CAP-China network. Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey. BMJ Open. 2018 Feb 15;8(2):e018709. doi: 10.1136/bmjopen-2017-018709.
PMID: 29449294DERIVED

MeSH Terms

Conditions

Community-Acquired Pneumonia

Condition Hierarchy (Ancestors)

Community-Acquired InfectionsInfectionsPneumoniaRespiratory Tract InfectionsRespiratory Tract Diseases

Study Officials

Bin Cao, MD
China-Japan Friendship Hospital
STUDY CHAIR

Central Study Contacts

Bin Cao, MD

CONTACT

86-010-84206264 caobin_ben@163.com

LI Gu, MD

CONTACT

86-010-85231514 guli2013227@foxmail.com.cn

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: MD

Study Record Dates

First Submitted

March 16, 2015

First Posted

July 3, 2015

Study Start

July 1, 2015

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

October 16, 2015

Record last verified: 2015-10

Locations

CN(1)

A Retrospective Study on Hospitalized Patients With Community-acquired Pneumonia in China (CAP-China)

Brief Summary

Trial Health

Trial Health Score

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (7)

Related Links

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Locations

Brief Summary

Trial Health

Trial Health Score

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (7)

Related Links

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Locations